A Phase 4 interventional study of Quetiapine fumarate XR and Lithium in Acute Mania, sponsored by AstraZeneca. Completed at 65 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-04-19.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Mania by AstraZeneca — none open to participants now, none under way, none of them phase 3. Mania · AstraZeneca.
Among the 10 studies in Mania by AstraZeneca, this one is the only one that started in 2009, is one of 4 in phase 4, and was the 6th registered.
167 studies on the registry are indexed under Mania; 14 are open to participants now.
Browse Mania studies →None of the 10 studies in Mania by AstraZeneca is open now. The open studies under Mania, anywhere →
Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 356 is above the median of 89 across 139 interventional studies indexed under Mania.
Median enrollment 141 across the 6 interventional studies, 341 across the 4 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Mania by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if lithium 600-1800 mg/day is effective when added to quetiapine fumarate extended release (quetiapine XR or SEROQUEL® XR) 400-800 mg/day in treating acute mania and if so, how it compares with placebo (a non-active capsule, like a sugar pill, that looks like lithium).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Seroquel XR and Lithium
Drug: Quetiapine fumarate XR · Drug: Lithium
Seroquel XR and placebo
Drug: Quetiapine fumarate XR · Drug: Placebo
Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
Also known as: Seroquel XR
Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
Oral treatment twice daily.
Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43)
The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).
Time frame: Change in YMRS total score from baseline to Day 43.
The Number of Patients With Clinically Significant Response.
The number of patients with clinically significant response (defined as ≥50% reduction from baseline to Day 43 in the YMRS total score) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.
Time frame: 43 days (from baseline to Day 43)
Remission
The number of patients with clinically significant remission (defined as YMRS total score ≤12) from Days 8 to 43) was calculated. The Young Mania Rating Scale total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).
Time frame: Days 8 to 43
Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness)
The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity.
Time frame: Change from baseline to Day 43.
Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase)
The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.
Time frame: Change from baseline to Day 43
Improvement of Overall Bipolar Illness
The number of patients with a CGI-BP-C of "Much" or "Very much" improved in overall bipolar illness assessment at Day 43 was calculated. The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.
Time frame: Day 43.
Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms.
Time frame: Change from baseline to Day 43.
Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210.A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in PANSS Activation Subscale Score
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in PANSS Positive Subscale Score
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 1
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 1 (Elevated mood) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 2
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 2 (increased motor activity-energy) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 3
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 3 (sexual interest) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 4
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 5
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 5 (Irritability) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 6
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 6 (speech-rate and amount) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 7
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 7 (language-thought disorder) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 8
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 8 (content) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 9
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. . This analysis is for Item 9 (disruptive-aggressive behavior) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 10
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 10 (appearance) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
Change From Baseline to Day 43 in Each YMRS Item Score No. 11
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 11 (insight) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
Time frame: Change from baseline to Day 43
This multicenter study was conducted between 24 June 2009 and 22 November 2010.
| Milestone | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Started | 173 | 183 |
| Completed | 147 | 144 |
| Not completed | 26 | 39 |
| Withdrew: Withdrawal by subject | 11 | 13 |
| Withdrew: Adverse event | 6 | 13 |
| Withdrew: Lithium found in blood | 0 | 1 |
| Withdrew: Condition under investigation worsened | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Study-specific discontinuation criteria | 1 | 1 |
| Withdrew: Severe non-compliance to protocol | 2 | 0 |
| Withdrew: Safety reasons | 0 | 1 |
| Withdrew: Took prohibited concomitant medication | 0 | 1 |
| Withdrew: Lack or insufficient theraputic response | 2 | 5 |
| Withdrew: Sponsor decision | 1 | 0 |
| Withdrew: Late hospital discharge | 1 | 0 |
The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43) | -22.8 ± 0.706 | -20.1 ± 0.711 |
The number of patients with clinically significant response (defined as ≥50% reduction from baseline to Day 43 in the YMRS total score) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms.
| Participants | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| The Number of Patients With Clinically Significant Response. | 137 | 120 |
The number of patients with clinically significant remission (defined as YMRS total score ≤12) from Days 8 to 43) was calculated. The Young Mania Rating Scale total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).
| Participants | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Remission | 125 | 105 |
The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness) | -2.5 ± 0.079 | -2.2 ± 0.080 |
The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase) | 1.7 ± 0.085 | 1.9 ± 0.086 |
The number of patients with a CGI-BP-C of "Much" or "Very much" improved in overall bipolar illness assessment at Day 43 was calculated. The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores \>4 indicate worsening, while scores \<4 indicate improvement.
| Participants | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Improvement of Overall Bipolar Illness | 134 | 125 |
The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | -4.8 ± 0.366 | -4.1 ± 0.368 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210.A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score | -19.2 ± 0.914 | -15.6 ± 0.914 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in PANSS Activation Subscale Score | -7.1 ± 0.281 | -5.9 ± 0.283 |
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in PANSS Positive Subscale Score | -8.1 ± 0.316 | -7.0 ± 0.316 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 1 (Elevated mood) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 1 | -1.8 ± 0.079 | -1.6 ± 0.080 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 2 (increased motor activity-energy) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 2 | -1.9 ± 0.071 | -1.7 ± 0.072 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 3 (sexual interest) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 3 | -1.3 ± 0.063 | -1.1 ± 0.064 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 4 | -2.0 ± 0.085 | -1.8 ± 0.086 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 5 (Irritability) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 5 | -3.1 ± 0.109 | -2.8 ± 0.110 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 6 (speech-rate and amount) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 6 | -3.1 ± 0.116 | -2.9 ± 0.118 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 7 (language-thought disorder) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 7 | -1.5 ± 0.071 | -1.4 ± 0.072 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 8 (content) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 8 | -3.1 ± 0.132 | -2.9 ± 0.133 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. . This analysis is for Item 9 (disruptive-aggressive behavior) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 9 | -2.5 ± 0.088 | -2.1 ± 0.089 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 10 (appearance) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 10 | -1.1 ± 0.057 | -1.0 ± 0.057 |
The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 11 (insight) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.
| Scores on a scale | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| Change From Baseline to Day 43 in Each YMRS Item Score No. 11 | -1.4 ± 0.069 | -1.2 ± 0.070 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lithium+Quetiapine XR | — | 4/173 (2.3%) | 106/173 (61.3%) |
| Placebo+Quetiapine XR | — | 8/183 (4.4%) | 83/183 (45.4%) |
| Event | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| ManiaPsychiatric disorders | 3/173 | 6/183 |
| GastroenteritisInfections and infestations | 1/173 | 0/183 |
| Aggression; HostilityPsychiatric disorders | 0/173 | 1/183 |
| No Therapeutic ResponseInvestigations | 0/173 | 1/183 |
| Event | Lithium+Quetiapine XR | Placebo+Quetiapine XR |
|---|---|---|
| TremorNervous system disorders | 27/173 | 9/183 |
| SomnolenceNervous system disorders | 22/173 | 10/183 |
| ConstipationGastrointestinal disorders | 16/173 | 16/183 |
| Dry MouthGastrointestinal disorders | 14/173 | 14/183 |
| InsomniaPsychiatric disorders | 11/173 | 12/183 |
| DizzinessNervous system disorders | 11/173 | 8/183 |
| HeadacheNervous system disorders | 9/173 | 11/183 |
| PyrexiaGeneral disorders | 10/173 | 9/183 |
| DiarrhoeaGastrointestinal disorders | 8/173 | 2/183 |
| VomitingGastrointestinal disorders | 8/173 | 0/183 |
| Age Continuous(Years) | Lithium+Quetiapine XR | Placebo+Quetiapine XR | Total |
|---|---|---|---|
| Mean | 37.9 ± 12.71 | 38.8 ± 12.09 | 38.3 ± 12.39 |
| Sex: Female, Male(Participants) | Lithium+Quetiapine XR | Placebo+Quetiapine XR | Total |
|---|---|---|---|
| Female | 72 | 62 | 134 |
| Male | 101 | 121 | 222 |
The record gives a start of Jun 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lithium